预防心肌缺血再灌注损伤的药物研究进展  

Progress in the Drugs of Prevention Myocardial Ischemia Reperfusion Injury

作　　者：谭柳群 麦秋良 TAN Liu-qun;MAI Qiu-liang(Hospital of Guangxi Liuzhou leon and Steel（Group）Company,Liuzhou 545002,China)

机构地区：[1]广西柳州钢铁集团有限公司医院,柳州545002

出　　处：《海峡药学》2018年第10期97-100,共4页Strait Pharmaceutical Journal

摘　　要：在治疗突发性心肌梗死患者时,由于突然打开堵塞的冠脉,缺血心肌恢复再灌注后,引起细胞超微结构、功能、代谢及电生理等方面发生进一步的损伤,称为心肌缺血再灌注损伤(IRI)。近年来,如何减轻心肌缺血再灌注损伤成为心脏病学应用基础研究中的热点。本文从造成心肌缺血再灌注损伤的机制,在减轻心肌细胞氧化损伤、减缓心肌细胞钙超载、调节心肌细胞能量代谢方式、保护心肌内皮细胞、抑制心肌细胞炎症释放和抑制心肌细胞凋亡等方面,综述了近几年预防心肌缺血再灌注损伤的药物研究进展及展望。In the treatment of patients with acute myocardial infarction,clogged coronaryartery suddenly opens and ischemic myocardial recovers reperfusion,that lead tothe further damage of ultrastructure,function and metabolism and electrophysiological.The damage called myocardial ischemia-reperfusion injury （IRI）.In recent years,how to alleviate IRI becomes the hot point in cardiology applied basic research.In this paper,starting with the mechanism of myocardial ischemia reperfusion damage,we reviewed the drugs that reducing oxidative damage,reducingmyocardial cell calcium overload,regulating energy metabolism,protecting endothelial cells,inhibiting inflammatory release and inhibiting apoptosis,etc.to prevent myocardial ischemia-reperfusion injury.

关 键 词：心肌缺血再灌注损伤 机制 预防药物 

分 类 号：R969.4[医药卫生—药理学]